March 2024 in “Journal of Endocrinological Investigation” Finasteride treatment in rats changed the expression of genes related to psychiatric and neurological functions, and these changes persisted after stopping the drug.
February 2024 in “International journal of molecular sciences” Type 3 Innate Lymphoid Cells help maintain skin health and balance, and are involved in skin diseases and healing.
August 2023 in “International Journal of Molecular Sciences” Human skin xenografting could improve our understanding of skin development, renewal, and healing.
July 2023 in “Biomolecules” The new "whisker follicle microinjection assay" can test how different biomolecules affect hair growth and color.
The research identified key molecules that help hair matrix and dermal papilla cells communicate and influence hair growth in cashmere goats.
February 2023 in “Vaccines” COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.
January 2023 in “Skin appendage disorders” Hair loss is common in autoimmune diseases and can be an early sign of the condition, often requiring prompt treatment to prevent permanent damage.
December 2022 in “IntechOpen eBooks” 308 excimer phototherapy is a safe and effective way to treat hair loss from Alopecia Areata.
Justicia procumbens extract may help prevent hair loss and improve hair thickness and shine in a type of hair loss condition.
16 citations,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
3 citations,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
1 citations,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
1 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
1 citations,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
1 citations,
November 2018 in “immuneACCESS” Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
April 2024 in “Liječnički vjesnik” Modern treatments can effectively regrow hair and improve life for people with alopecia areata.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
8 citations,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.